ClinicalTrials.gg
CompletedNCT04833855INCEPTIONUpdated Apr 9, 2025Results posted

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

A Phase 2 interventional study of Tezepelumab Dose 1 and Tezepelumab Dose 2 in Chronic Spontaneous Urticaria, sponsored by Amgen. Completed at 81 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.

Enrollment
23rd of 58
183 · median 132
Started
2021
with 3 others
Phase 2
23 of 64
4 open now
Registered
31st of 64
by date

Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 23rd largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2021, is one of 23 in phase 2, and was the 31st registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 48 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Chronic Urticaria with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of tezepelumab on improvement in the Urticaria Activity Score over 7 days (UAS7).

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • CSU
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study.
  • Male and female participants ≥ 18 years and ≤ 80 years of age at the time of screening.
  • Chronic spontaneous urticaria (CSU) diagnosis for ≥ 6 months at the time of screening.
  • CSU inadequately controlled by second generation H1-antihistamines (sgAH) at enrollment, as defined by all of the following:
  • The presence of itch and hives for >= 6 consecutive weeks at any time prior to screening visit 2
  • Failure to respond to an sgAH (up to 4 times the approved dose)
  • Urticaria Activity Score over 7 days (UAS7) (range 0-42) >= 16 and Hives Severity Score over 7 days (HSS7) (range 0-21) >= 8 during the 7 days prior to enrollment
  • Participant with CSU who discontinued, is intolerant to, or was an inadequate responder to anti-IgE therapies despite being treated with omalizumab 300 mg every 4 weeks (Q4W) for 6 months or higher doses of omalizumab > 2 months or another anti-IgE therapy. Note: This criterion is only applicable for anti-IgE-experienced participants.
  • Participant willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules.
  • Subject must have been on a sgAH at approved or increased doses (up to 4x the approved dose) for treatment of CSU for at least 3 consecutive days immediately prior to the day -14 screening visit (screening visit 2) and must have documented current use on the day of screening visit 1

Exclusion criteria

Exclusion Criteria:

Disease related, including but not limited to:

  • Urticaria is solely due to inducible urticaria
  • Active dermatologic diseases (or conditions) other than chronic urticaria, with urticaria wheals or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema (eg, due to C1 inhibitor deficiency)
  • Any other active skin disease associated with chronic itching that might influence, in the investigator's opinion, the study evaluations and results (eg, atopic dermatitis, dermatitis herpetiformis, senile pruritus, etc.)
  • History of a infection within 28 days prior to day 1 that, in the opinion of the investigator or medical monitor, might compromise the safety of the participant in the study, interfere with evaluation of the product, or reduce the participants ability to participate in the study.
  • Evidence of active tuberculosis (TB) (in the opinion of the investigator), either treated or untreated, or a positive purified protein derivative (PPD) or QuantiFERON-TB Gold Plus (QFT-Plus) test for TB during screening.
  • History of , except for basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy ≥ 12 months prior to screening or other malignancies treated with apparent success with curative therapy ≥ 5 years prior to screening visit 1.
  • Subject is unable to complete an electronic patient diary or complete questionnaires, or does not meet the required level of compliance with the eDiary during the 14 days sgAH stabilization period

Other medical conditions

  • History or evidence of severe depression, schizophrenia, previous suicide attempts, or suicidal ideation.

Prior/concomitant therapy, including but not limited to:

  • Treatment with any biologic products (eg, omalizumab, ligelizumab) within 4 months or 5 half-lives (whichever is longer) prior to screening visit 1
  • Routine (daily or every other day for 5 or more consecutive days) use of systemic , systemic hydroxychloroquine, methotrexate, cyclosporine A, cyclophosphamide, tacrolimus, azathioprine, and mycophenolate mofetil within 30 days prior to screening visit 1.
  • Major surgery within 8 weeks prior to screening visit 1 or planned inpatient surgery or hospitalization during the study period.
  • Receipt of Ig or blood products within 30 days prior to screening visit 1.
  • Vaccination with a live or attenuated vaccine within 30 days prior to screening visit 1. Receipt of COVID-19 vaccines and inactive/killed vaccinations (eg, inactive influenza) are allowed, provided the vaccinations are not administered within 7 days before or after any study dosing visit.
  • Known , including severe hypersensitivity reactions and/or history of anaphylactic shock, to any of the products or components to be administered during dosing or to products of similar chemical classes (ie, to murine, chimeric, or human antibodies.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
183 participants (actual)

Study arms

  • Active comparator
    Group 1: Omalizumab

    Participants naive to anti-IgE therapies will receive omalizumab.

    Biological: Omalizumab

  • Placebo comparator
    Group 2: Placebo

    Participants naive to anti-IgE therapies will receive a placebo.

    Biological: Placebo

  • Experimental
    Group 3: Tezepelumab Dose 1

    Participants naive to anti-IgE therapies will receive tezepelumab.

    Biological: Tezepelumab Dose 1

  • Experimental
    Group 4: Tezepelumab Dose 2

    Participants naive to anti-IgE therapies will receive tezepelumab.

    Biological: Tezepelumab Dose 2

  • Placebo comparator
    Group 5: Placebo

    Participants previously treated with anti-IgE therapies will receive a placebo.

    Biological: Placebo

  • Experimental
    Group 6: Tezepelumab Dose 1

    Participants previously treated with anti-IgE therapies will receive tezepelumab.

    Biological: Tezepelumab Dose 1

  • Experimental
    Group 7: Tezepelumab Dose 2

    Participants previously treated with anti-IgE therapies will receive tezepelumab.

    Biological: Tezepelumab Dose 2

Interventions

  • Subcutaneous injection.

    Also known as: AMG 157

  • Subcutaneous injection.

    Also known as: AMG 157

  • BiologicalOmalizumab

    Subcutaneous injection.

    Also known as: Xolair

  • BiologicalPlacebo

    Subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16

    The UAS is a CSU-specific patient-reported outcome measure with 2 components: Hives Severity Score (HSS) for number of wheals and an Itch Severity Score (ISS) for itch intensity, and are each scored from 0 (no wheals, no itch) to 3 (\>50 wheals, severe itch) for the previous 24 hours. The HSS and ISS are combined to give a daily UAS ranging from 0 to 6. The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). The least squares mean (LSM) estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline UAS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Change From Baseline in ISS Over 7 Days (ISS7) at Week 16

    The ISS is a component of the UAS, a CSU-specific patient-reported outcome measure and assessed itch intensity, with daily scores ranging from 0 (no itch) to 3 (severe itch) for the previous 24 hours. The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline ISS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.

    Time frame: Baseline and Week 16

  2. Change From Baseline in HSS Over 7 Days (HSS7) at Week 16

    The HSS is a component of the UAS, a CSU-specific patient-reported outcome measure and assessed the number of wheals, with daily scores ranging from 0 (no wheals) to 3 (\>50 wheals) for the previous 24 hours. The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline HSS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.

    Time frame: Baseline and Week 16

  3. Number of Participants With a UAS7 of ≤ 6 (Minimal Residual Disease) at Week 16

    The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). Minimal residual disease in UAS7 was defined as a score ≤ 6 and indicates well-controlled urticaria and a good response to treatment.

    Time frame: Week 16

  4. Number of Participants With a Change From Baseline in UAS7 of ≤ -10 (Minimal Important Difference)

    The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). Minimal important difference in UAS7 was defined as a change from baseline of ≤ -10.

    Time frame: Baseline and Week 16

  5. Number of Participants With a UAS7 = 0 at Week 16 (Complete Response)

    The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). A complete response was defined as UAS7 = 0 at Week 16.

    Time frame: Week 16

  6. Number of Participants With ISS7 = 0 at Week 16 (Complete Resolution)

    The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). An ISS7 = 0 indicates a complete resolution of itch.

    Time frame: Week 16

  7. Number of Participants With a Change From Baseline in ISS7 of ≤ -5 (Minimal Important Difference)

    The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). Minimal important difference in ISS7 was defined as a change from baseline of ≤ -5.

    Time frame: Baseline and Week 16

  8. Number of Participants With HSS7 = 0 at Week 16 (Complete Resolution)

    The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). An HSS7 = 0 indicates a complete resolution of hives.

    Time frame: Week 16

  9. Number of Participants With a Change From Baseline in HSS7 of ≤ -5.5 (Minimal Important Difference)

    The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). Minimal important difference in HSS7 was defined as a change from baseline of ≤ -5.5.

    Time frame: Baseline and Week 16

  10. Change From Baseline in Weekly Sleep Interference Score (SIS7) at Week 16

    The SIS is part of the Urticaria Patient Daily Diary and was assessed by the participant using the electronic diary once daily in the morning. Participants scored sleep interference on a scale of 0 (no interference) to 3 (substantial, woke up often, severe interference with sleep). The SIS7 was a sum of the daily scores over 7 days ranging from 0 to 21. The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SIS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep interference.

    Time frame: Baseline and Week 16

  11. Change From Baseline in Weekly Sleep Quality Score (SQS7): Sum of Daily SQS at Week 16

    The SQS was assessed by the participant through 3 questions relating to falling asleep (Q1), wakefulness (Q2), and feeling rested in the morning (Q3). The sum of the 3 daily sleep quality items over 7 days, ranged from 0 (good quality sleep) to 63 (poor quality sleep). The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SQS7 - sum of SQS, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep quality.

    Time frame: Baseline and Week 16

  12. Change From Baseline in SQS7: Sum of Average Daily Q1 - Q3 at Week 16

    The SQS was assessed by the participant through 3 questions relating to falling asleep (Q1), wakefulness (Q2), and feeling rested in the morning (Q3). The sum of average daily Q1 - Q3 score was generated by averaging 3 daily sleep quality items and then summing the daily average over 7 days with a score ranging from 0 (good quality sleep) to 21 (poor quality sleep) (sum of the average daily Q1 - Q3). The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SQS7 - sum of average daily Q1 - Q3, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep quality.

    Time frame: Baseline and Week 16

  13. Change From Baseline in Urticaria Control Test (UCT) Score at Week 16

    The UCT assesses disease control in participants with CSU through a retrospective validated scoring system, evaluating the physical symptoms of chronic urticaria (itch, hives and/or angioedema) and the effectiveness of treatment over 4 weeks. It consists of 4 questions with 5 answer options, scored from 0 to 4, and the UCT score is the sum of all 4 questions, with total score ranging from 0 (no control) to 16 (complete control). A score of ≥ 12 indicates well-controlled urticaria and a score of ≤ 11 points indicates poor disease control. A positive change from baseline indicates an improvement in disease control. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline UCT score, treatment, study week and the interaction between treatment and study week.

    Time frame: Baseline and Week 16

  14. Change From Baseline in Weekly Angioedema Activity Score (AAS7) at Week 16

    The AAS is a 5-item patient-reported outcome measure used to determine angioedema activity. Participants retrospectively documented the presence or absence of angioedema in the past 24 hours, and the AAS daily score ranged from 0 to 15 points, assessing 5 key factors when angioedema is present, including duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity). The daily AAS scores are summed for 7 days to form the AAS7 with a range of 0 (not present) to 105 (most severe angioedema activity). Negative changes from baseline indicate an improvement in angioedema activity. The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AAS7, treatment, study week and the interaction between treatment and study week.

    Time frame: Baseline and Week 16

  15. Number of Cumulative Weeks That Participants Achieved AAS7 = 0 at Week 16 (Angioedema Occurrence Free)

    The AAS is a 5-item patient-reported outcome measure used to determine angioedema activity. Participants retrospectively documented the presence or absence of angioedema in the past 24 hours, and the AAS daily score ranged from 0 to 15 points, assessing 5 key factors when angioedema is present, including duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity). The daily AAS scores are summed for 7 days to form the AAS7 with a range of 0 (not present) to 105 (most severe angioedema activity). Angioedema occurrence free was defined as AAS7 = 0.

    Time frame: Baseline to Week 16

  16. Change From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Week 16

    The CU-Q2oL is a 23-item, self-reported urticaria-specific measure to evaluate 6 dimensions of quality of life (QoL): pruritus, impact on life activities, sleep problems, limitations, looks, and swelling. The total score is transformed to a linear scale of 0 to 100 with a higher CU-Q2oL score indicating a higher QoL impairment. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline CU-Q2oL score, treatment, study week and the interaction between treatment and study week.

    Time frame: Baseline and Week 16

  17. Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16

    The DLQI is a 10-item, participant-completed, health-related QoL assessment with content specific to those with dermatology conditions. The DLQI evaluates participant perceptions including dermatology-related symptoms and feelings, impacts on daily activities, leisure, work or school, personal relationships, and side effects of treatment. The recall period was 1 week. The DLQI total score ranges from 0 to 30 with a higher score indicating a greater QoL impairment. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline DLQI score, treatment, study week and the interaction between treatment and study week.

    Time frame: Baseline and Week 16

  18. Change From Baseline in the Angioedema Quality of Life Questionnaire (AE-QoL) at Week 16

    The AE-QoL is a validated angioedema QoL questionnaire for participants with angioedema. It consists of 17 questions evaluating 4 domains including functioning, fatigue/mood, fear/shame, and food with a recall period of 4 weeks. The total score is transformed to a linear scale ranging from 0 to 100, with a higher score indicating a worse impairment in QoL. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AE-QoL score, treatment, study week and the interaction between treatment and study week.

    Time frame: Baseline and Week 16

  19. Change From Baseline in the Angioedema Control Test (AECT) Score at Week 16

    The AECT is a patient-reported outcome measure to evaluate disease control in the domains of signs and symptoms, QoL, anxiety/fear, and effectiveness of therapy. The total AECT score ranges from 0 to 16, with higher scores indicating well-controlled disease. A positive change from baseline indicates an improvement in angioedema control. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AECT score, treatment, study week and the interaction between treatment and study week.

    Time frame: Baseline and Week 16

  20. Number of Participants With an AECT Score = 16 at Week 16 (Complete Control)

    The total AECT score ranges from 0 to 16, with higher scores indicating better controlled disease. Complete control was defined as AECT score = 16.

    Time frame: Baseline and Week 16

  21. Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16

    The WPAI-CU is a questionnaire that assesses the impact of an intervention on work productivity, evaluating 4 areas including absenteeism, presenteeism, work productivity loss, and activity impairment over the past 7 days. Each of the areas is scored separately as a percentage, ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity. A negative change from baseline indicates an improvement. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline WPAI-CU score, treatment, study week and the interaction between treatment and study week.

    Time frame: Baseline and Week 16

  22. Number of Cumulative Days of sgAH Rescue Medication Use From Baseline to Week 16

    Participants recorded any need of sgAH rescue medication in their daily electronic diary.

    Time frame: Baseline to Week 16

  23. Serum Concentration of Tezepelumab

    The lower limit of quantification was 10 ng/mL, and values below this limit were set to zero.

    Time frame: Week 1 pre-dose, Weeks 2, 4, 8, 12, 16, 24, and 32

  24. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with study treatment. TEAEs were AEs that started on or after the first dose of investigational product up to the end of study (Week 32). A serious AE (SAE) was defined as any untoward medical occurrence that met at least 1 of the following serious criteria: immediately life-threatening, required hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or other medically important serious event.

    Time frame: Day 1 Week 1 to Week 32, up to 32 weeks

07

Results

Posted May 1, 2024

Participant flow

Participants were enrolled at 56 study centers in Japan, Republic of Korea, France, Germany, Greece, Italy, Poland, Spain, Canada, and the United States, and participated from 15 April 2021 to 13 April 2023.

Participant flow — Overall Study
MilestonePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Started48315252
Completed43294548
Not completed5274
Withdrew: Decision by sponsor0100
Withdrew: Withdrawal by subject4131
Withdrew: Lost to follow-up1022
Withdrew: Protocol specified criteria0021

Outcome measures

PrimaryChange From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16

The UAS is a CSU-specific patient-reported outcome measure with 2 components: Hives Severity Score (HSS) for number of wheals and an Itch Severity Score (ISS) for itch intensity, and are each scored from 0 (no wheals, no itch) to 3 (\>50 wheals, severe itch) for the previous 24 hours. The HSS and ISS are combined to give a daily UAS ranging from 0 to 6. The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). The least squares mean (LSM) estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline UAS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16-13.6 ± 1.6-18.4 ± 2.0-13.5 ± 1.6-14.7 ± 1.5
Statistical analysis
  • Placebo vs Tezepelumab 210 mg SC Q4W · Repeated measure model · p = 0.99 (Nominal p-value) · Lsm difference: 0.0 · 95% CI -4.3 to 4.4Tezepelumab 210 mg SC Q4W - Placebo
  • Placebo vs Tezepelumab 420 mg SC Q2W · Repeated measure model · p = 0.60 (Nominal p-value) · Lsm difference: -1.1 · 95% CI -5.4 to 3.1Tezepelumab 420 mg SC Q2W - Placebo
SecondaryChange From Baseline in ISS Over 7 Days (ISS7) at Week 16

The ISS is a component of the UAS, a CSU-specific patient-reported outcome measure and assessed itch intensity, with daily scores ranging from 0 (no itch) to 3 (severe itch) for the previous 24 hours. The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline ISS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in ISS Over 7 Days (ISS7) at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Change From Baseline in ISS Over 7 Days (ISS7) at Week 16-7.7 ± 0.8-9.6 ± 1.0-7.3 ± 0.8-8.0 ± 0.8
SecondaryChange From Baseline in HSS Over 7 Days (HSS7) at Week 16

The HSS is a component of the UAS, a CSU-specific patient-reported outcome measure and assessed the number of wheals, with daily scores ranging from 0 (no wheals) to 3 (\>50 wheals) for the previous 24 hours. The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline HSS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in HSS Over 7 Days (HSS7) at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Change From Baseline in HSS Over 7 Days (HSS7) at Week 16-5.8 ± 0.8-8.8 ± 1.1-6.3 ± 0.8-6.7 ± 0.8
SecondaryNumber of Participants With a UAS7 of ≤ 6 (Minimal Residual Disease) at Week 16

The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). Minimal residual disease in UAS7 was defined as a score ≤ 6 and indicates well-controlled urticaria and a good response to treatment.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With a UAS7 of ≤ 6 (Minimal Residual Disease) at Week 16
ParticipantsPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Number of Participants With a UAS7 of ≤ 6 (Minimal Residual Disease) at Week 168141013
SecondaryNumber of Participants With a Change From Baseline in UAS7 of ≤ -10 (Minimal Important Difference)

The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). Minimal important difference in UAS7 was defined as a change from baseline of ≤ -10.

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
Number of Participants With a Change From Baseline in UAS7 of ≤ -10 (Minimal Important Difference)
ParticipantsPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Number of Participants With a Change From Baseline in UAS7 of ≤ -10 (Minimal Important Difference)28202732
SecondaryNumber of Participants With a UAS7 = 0 at Week 16 (Complete Response)

The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). A complete response was defined as UAS7 = 0 at Week 16.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With a UAS7 = 0 at Week 16 (Complete Response)
ParticipantsPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Number of Participants With a UAS7 = 0 at Week 16 (Complete Response)41175
SecondaryNumber of Participants With ISS7 = 0 at Week 16 (Complete Resolution)

The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). An ISS7 = 0 indicates a complete resolution of itch.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With ISS7 = 0 at Week 16 (Complete Resolution)
ParticipantsPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Number of Participants With ISS7 = 0 at Week 16 (Complete Resolution)41279
SecondaryNumber of Participants With a Change From Baseline in ISS7 of ≤ -5 (Minimal Important Difference)

The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). Minimal important difference in ISS7 was defined as a change from baseline of ≤ -5.

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
Number of Participants With a Change From Baseline in ISS7 of ≤ -5 (Minimal Important Difference)
ParticipantsPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Number of Participants With a Change From Baseline in ISS7 of ≤ -5 (Minimal Important Difference)29202834
SecondaryNumber of Participants With HSS7 = 0 at Week 16 (Complete Resolution)

The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). An HSS7 = 0 indicates a complete resolution of hives.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With HSS7 = 0 at Week 16 (Complete Resolution)
ParticipantsPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Number of Participants With HSS7 = 0 at Week 16 (Complete Resolution)61186
SecondaryNumber of Participants With a Change From Baseline in HSS7 of ≤ -5.5 (Minimal Important Difference)

The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). Minimal important difference in HSS7 was defined as a change from baseline of ≤ -5.5.

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
Number of Participants With a Change From Baseline in HSS7 of ≤ -5.5 (Minimal Important Difference)
ParticipantsPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Number of Participants With a Change From Baseline in HSS7 of ≤ -5.5 (Minimal Important Difference)23192431
SecondaryChange From Baseline in Weekly Sleep Interference Score (SIS7) at Week 16

The SIS is part of the Urticaria Patient Daily Diary and was assessed by the participant using the electronic diary once daily in the morning. Participants scored sleep interference on a scale of 0 (no interference) to 3 (substantial, woke up often, severe interference with sleep). The SIS7 was a sum of the daily scores over 7 days ranging from 0 to 21. The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SIS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep interference.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Sleep Interference Score (SIS7) at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Change From Baseline in Weekly Sleep Interference Score (SIS7) at Week 16-8.4 ± 0.7-6.5 ± 0.9-7.4 ± 0.7-7.8 ± 0.7
SecondaryChange From Baseline in Weekly Sleep Quality Score (SQS7): Sum of Daily SQS at Week 16

The SQS was assessed by the participant through 3 questions relating to falling asleep (Q1), wakefulness (Q2), and feeling rested in the morning (Q3). The sum of the 3 daily sleep quality items over 7 days, ranged from 0 (good quality sleep) to 63 (poor quality sleep). The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SQS7 - sum of SQS, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep quality.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Sleep Quality Score (SQS7): Sum of Daily SQS at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Change From Baseline in Weekly Sleep Quality Score (SQS7): Sum of Daily SQS at Week 16-19.5 ± 1.8-16.7 ± 2.3-18.3 ± 1.7-17.1 ± 1.6
SecondaryChange From Baseline in SQS7: Sum of Average Daily Q1 - Q3 at Week 16

The SQS was assessed by the participant through 3 questions relating to falling asleep (Q1), wakefulness (Q2), and feeling rested in the morning (Q3). The sum of average daily Q1 - Q3 score was generated by averaging 3 daily sleep quality items and then summing the daily average over 7 days with a score ranging from 0 (good quality sleep) to 21 (poor quality sleep) (sum of the average daily Q1 - Q3). The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SQS7 - sum of average daily Q1 - Q3, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep quality.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in SQS7: Sum of Average Daily Q1 - Q3 at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Change From Baseline in SQS7: Sum of Average Daily Q1 - Q3 at Week 16-6.5 ± 0.6-5.6 ± 0.8-6.1 ± 0.6-5.7 ± 0.5
SecondaryChange From Baseline in Urticaria Control Test (UCT) Score at Week 16

The UCT assesses disease control in participants with CSU through a retrospective validated scoring system, evaluating the physical symptoms of chronic urticaria (itch, hives and/or angioedema) and the effectiveness of treatment over 4 weeks. It consists of 4 questions with 5 answer options, scored from 0 to 4, and the UCT score is the sum of all 4 questions, with total score ranging from 0 (no control) to 16 (complete control). A score of ≥ 12 indicates well-controlled urticaria and a score of ≤ 11 points indicates poor disease control. A positive change from baseline indicates an improvement in disease control. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline UCT score, treatment, study week and the interaction between treatment and study week.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Urticaria Control Test (UCT) Score at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Change From Baseline in Urticaria Control Test (UCT) Score at Week 164.1 ± 0.66.3 ± 0.84.9 ± 0.65.9 ± 0.6
SecondaryChange From Baseline in Weekly Angioedema Activity Score (AAS7) at Week 16

The AAS is a 5-item patient-reported outcome measure used to determine angioedema activity. Participants retrospectively documented the presence or absence of angioedema in the past 24 hours, and the AAS daily score ranged from 0 to 15 points, assessing 5 key factors when angioedema is present, including duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity). The daily AAS scores are summed for 7 days to form the AAS7 with a range of 0 (not present) to 105 (most severe angioedema activity). Negative changes from baseline indicate an improvement in angioedema activity. The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AAS7, treatment, study week and the interaction between treatment and study week.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Angioedema Activity Score (AAS7) at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Change From Baseline in Weekly Angioedema Activity Score (AAS7) at Week 16-19.0 ± 2.7-18.7 ± 3.5-20.8 ± 2.7-15.6 ± 2.5
SecondaryNumber of Cumulative Weeks That Participants Achieved AAS7 = 0 at Week 16 (Angioedema Occurrence Free)

The AAS is a 5-item patient-reported outcome measure used to determine angioedema activity. Participants retrospectively documented the presence or absence of angioedema in the past 24 hours, and the AAS daily score ranged from 0 to 15 points, assessing 5 key factors when angioedema is present, including duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity). The daily AAS scores are summed for 7 days to form the AAS7 with a range of 0 (not present) to 105 (most severe angioedema activity). Angioedema occurrence free was defined as AAS7 = 0.

Time frame:
Baseline to Week 16
Reported as:
Mean · weeks
Number of Cumulative Weeks That Participants Achieved AAS7 = 0 at Week 16 (Angioedema Occurrence Free)
weeksPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Number of Cumulative Weeks That Participants Achieved AAS7 = 0 at Week 16 (Angioedema Occurrence Free)10.8 ± 5.211.3 ± 4.99.9 ± 5.811.5 ± 5.4
SecondaryChange From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Week 16

The CU-Q2oL is a 23-item, self-reported urticaria-specific measure to evaluate 6 dimensions of quality of life (QoL): pruritus, impact on life activities, sleep problems, limitations, looks, and swelling. The total score is transformed to a linear scale of 0 to 100 with a higher CU-Q2oL score indicating a higher QoL impairment. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline CU-Q2oL score, treatment, study week and the interaction between treatment and study week.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Change From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Week 16-19.6 ± 2.1-19.8 ± 2.8-19.3 ± 2.2-18.7 ± 2.1
SecondaryChange From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16

The DLQI is a 10-item, participant-completed, health-related QoL assessment with content specific to those with dermatology conditions. The DLQI evaluates participant perceptions including dermatology-related symptoms and feelings, impacts on daily activities, leisure, work or school, personal relationships, and side effects of treatment. The recall period was 1 week. The DLQI total score ranges from 0 to 30 with a higher score indicating a greater QoL impairment. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline DLQI score, treatment, study week and the interaction between treatment and study week.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16-7.4 ± 0.9-7.3 ± 1.2-7.0 ± 0.9-7.0 ± 0.9
SecondaryChange From Baseline in the Angioedema Quality of Life Questionnaire (AE-QoL) at Week 16

The AE-QoL is a validated angioedema QoL questionnaire for participants with angioedema. It consists of 17 questions evaluating 4 domains including functioning, fatigue/mood, fear/shame, and food with a recall period of 4 weeks. The total score is transformed to a linear scale ranging from 0 to 100, with a higher score indicating a worse impairment in QoL. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AE-QoL score, treatment, study week and the interaction between treatment and study week.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Angioedema Quality of Life Questionnaire (AE-QoL) at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Change From Baseline in the Angioedema Quality of Life Questionnaire (AE-QoL) at Week 16-29.2 ± 6.0-24.1 ± 10.9-24.6 ± 6.4-13.1 ± 7.4
SecondaryChange From Baseline in the Angioedema Control Test (AECT) Score at Week 16

The AECT is a patient-reported outcome measure to evaluate disease control in the domains of signs and symptoms, QoL, anxiety/fear, and effectiveness of therapy. The total AECT score ranges from 0 to 16, with higher scores indicating well-controlled disease. A positive change from baseline indicates an improvement in angioedema control. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AECT score, treatment, study week and the interaction between treatment and study week.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Angioedema Control Test (AECT) Score at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Change From Baseline in the Angioedema Control Test (AECT) Score at Week 164.2 ± 1.23.9 ± 2.24.6 ± 1.32.3 ± 1.5
SecondaryNumber of Participants With an AECT Score = 16 at Week 16 (Complete Control)

The total AECT score ranges from 0 to 16, with higher scores indicating better controlled disease. Complete control was defined as AECT score = 16.

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
Number of Participants With an AECT Score = 16 at Week 16 (Complete Control)
ParticipantsPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Number of Participants With an AECT Score = 16 at Week 16 (Complete Control)3201
SecondaryChange From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16

The WPAI-CU is a questionnaire that assesses the impact of an intervention on work productivity, evaluating 4 areas including absenteeism, presenteeism, work productivity loss, and activity impairment over the past 7 days. Each of the areas is scored separately as a percentage, ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity. A negative change from baseline indicates an improvement. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline WPAI-CU score, treatment, study week and the interaction between treatment and study week.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16
score on a scalePlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Absenteeism-4.7 ± 2.50.3 ± 3.0-7.5 ± 2.5-2.3 ± 2.7
Presenteeism-19.9 ± 5.2-18.3 ± 6.6-20.3 ± 5.3-17.8 ± 5.7
Work productivity loss-20.0 ± 5.4-13.3 ± 6.7-23.5 ± 5.5-17.5 ± 5.9
Activity impairment-28.5 ± 4.2-30.3 ± 5.6-27.2 ± 4.3-24.1 ± 4.1
SecondaryNumber of Cumulative Days of sgAH Rescue Medication Use From Baseline to Week 16

Participants recorded any need of sgAH rescue medication in their daily electronic diary.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · days
Number of Cumulative Days of sgAH Rescue Medication Use From Baseline to Week 16
daysPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Number of Cumulative Days of sgAH Rescue Medication Use From Baseline to Week 1649.5 ± 39.031.6 ± 42.746.1 ± 39.332.7 ± 33.4
SecondarySerum Concentration of Tezepelumab

The lower limit of quantification was 10 ng/mL, and values below this limit were set to zero.

Time frame:
Week 1 pre-dose, Weeks 2, 4, 8, 12, 16, 24, and 32
Reported as:
Mean · µg/mL
Serum Concentration of Tezepelumab
µg/mLTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Week 10.00 ± 0.000.00 ± 0.00
Week 220.1 ± 6.9341.3 ± 12.4
Week 414.2 ± 5.7871.3 ± 20.8
Week 821.2 ± 8.54101 ± 30.5
Week 1224.8 ± 9.67123 ± 44.1
Week 1627.1 ± 10.7136 ± 43.4
Week 246.95 ± 5.6537.3 ± 21.1
Week 321.73 ± 1.7311.0 ± 10.8
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with study treatment. TEAEs were AEs that started on or after the first dose of investigational product up to the end of study (Week 32). A serious AE (SAE) was defined as any untoward medical occurrence that met at least 1 of the following serious criteria: immediately life-threatening, required hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or other medically important serious event.

Time frame:
Day 1 Week 1 to Week 32, up to 32 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
TEAEs23242928
SAEs0110

Adverse events

Collected over All-cause mortality was collected from enrolment to the end of study visit, up to 38 weeks. SAEs and other AEs were collected from Day 1 up to Week 32, up to 32 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/48 (0%)0/48 (0%)14/48 (29.2%)
Omalizumab 300 mg SC Q4W0/31 (0%)1/31 (3.2%)7/31 (22.6%)
Tezepelumab 210 mg SC Q4W0/52 (0%)1/52 (1.9%)19/52 (36.5%)
Tezepelumab 420 mg SC Q2W0/52 (0%)0/52 (0%)20/52 (38.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
Intentional self-injuryPsychiatric disorders0/481/310/520/52
Acute lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/480/311/520/52
Most frequent other events
Most frequent other events
EventPlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2W
COVID-19Infections and infestations3/482/318/525/52
HeadacheNervous system disorders2/481/315/526/52
PyrexiaGeneral disorders1/483/313/522/52
UrticariaSkin and subcutaneous tissue disorders4/480/314/523/52
Injection site painGeneral disorders1/480/314/521/52
EczemaSkin and subcutaneous tissue disorders3/481/312/520/52
NasopharyngitisInfections and infestations2/481/311/523/52
Back painMusculoskeletal and connective tissue disorders0/480/311/523/52
CoughRespiratory, thoracic and mediastinal disorders0/480/312/523/52

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2WTotal
Mean42.8 ± 15.239.8 ± 13.145.0 ± 14.742.9 ± 14.542.9 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2WTotal
Female37233539134
Male118171349
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2WTotal
Hispanic or Latino323614
Not Hispanic or Latino45294946169
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboOmalizumab 300 mg SC Q4WTezepelumab 210 mg SC Q4WTezepelumab 420 mg SC Q2WTotal
Asian1812161460
Black or African American12227
Multiple00011
White29173434114
Other00011
08

Study locations

81 sites
  • Clinical Research Center of Alabama
    Birmingham, Alabama 35209, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Avance Clinical Trials
    Laguna Niguel, California 92677, United States
  • Jonathan Corren MD Inc
    Los Angeles, California 90025, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Asthma and Allergy Associates PC
    Colorado Springs, Colorado 80907, United States
  • The Community Research of South Florida
    Miami Lakes, Florida 33016, United States
  • Advanced Medical Research PC
    Sandy Springs, Georgia 30328, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Epiphany Dermatology of Kansas, LLC
    Overland Park, Kansas 66210, United States
  • Bluegrass Allergy Care
    Lexington, Kentucky 40509, United States
  • Family Allergy and Asthma Research Institute
    Louisville, Kentucky 40215, United States
  • Johns Hopkins Asthma and Allergy Center
    Baltimore, Maryland 21224, United States
  • David Fivenson MD Professional Liability Company
    Ann Arbor, Michigan 48103, United States
  • Clarkston Skin Research
    Clarkston, Michigan 48346, United States
  • Henry Ford Medical Center - New Center One
    Detroit, Michigan 48202, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Bernstein Clinical Research Center LLC
    Cincinnati, Ohio 45236, United States
  • Aventiv Research Inc
    Dublin, Ohio 43016, United States
  • Clinical Partners LLC
    Johnston, Rhode Island 02919, United States
  • The Allergy Asthma and Sinus Center, East Tennessee Center for Clinical Research
    Knoxville, Tennessee 37909, United States
  • Suzanne Bruce and Associates
    Houston, Texas 77056, United States
  • Cutis Wellness Dermatology and Dermatopathology, PLLC
    Laredo, Texas 78041, United States
  • Dermatology Research Institute Incorporated
    Calgary, Alberta T2J 7E1, Canada
  • Brunswick Dermatology Centre
    Fredericton, New Brunswick E3B 1G9, Canada
  • LEADER Research
    Hamilton, Ontario L8L 3C3, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P 1X3, Canada
  • Cheema Research Incorporated
    Mississauga, Ontario L5A 3V4, Canada
  • Dr. S. K. Siddha Medicine Professional Corporation
    Newmarket, Ontario L3Y 5G8, Canada
  • Allergy Research Canada Incorporated
    Niagara Falls, Ontario L2H 1H5, Canada
  • Gordon Sussman Clinical Research Incorporated
    North York, Ontario M3B 3S6, Canada
  • Clinique Spécialisée en Allergie de la Capitale
    Quebec, G1V 4W2, Canada
  • Centre Hospitalier Universitaire de Brest - Hôpital Morvan
    Brest, 29200, France
  • Centre Hospitalier Universitaire de Grenoble - Hopital Nord Michallon
    Grenoble Cedex 9, 38043, France
  • Hôpital Saint Eloi
    Montpellier cedex 5, 34295, France
  • Centre Hospitalier Universitaire Archet 2
    Nice, 06202, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite Cedex, 69495, France
  • *Charité*
    Berlin, 12203, Germany
  • Universitaetsklinikum Dresden
    Dresden, 01307, Germany
  • Johannes Gutenberg Universitaet Mainz
    Mainz, 55101, Germany
  • Laiko General Hospital of Athens
    Athens, 11527, Greece
  • Sotiria General Hospital
    Athens, 11527, Greece
  • Attikon University General Hospital of Athens
    Athens, 12462, Greece
  • Andreas Syggros Hospital
    Athens, 16121, Greece
  • George Papageorgiou General Hospital of Thessaloniki
    Thessaloniki, 56403, Greece
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • Azienda Ospedaliero Universitaria di Modena
    Modena, 41124, Italy
  • Fondazione Policlinico Tor Vergata
    Roma, 00133, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • IRCCS Istituto Clinico Humanitas
    Rozzano MI, 20089, Italy
  • Azienda Ospedaliera Citta della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • Fujita Health University Bantane Hospital
    Nagoya-shi, Aichi 454-8509, Japan
  • Hiroshima University Hospital
    Hiroshima-shi, Hiroshima 734-8551, Japan
  • Takagi Dermatological Clinic
    Obihiro-shi, Hokkaido 080-0013, Japan
  • Kosugi Dermatology Clinic
    Kawasaki-shi, Kanagawa 211-0063, Japan
  • Nomura Dermatology Clinic
    Yokohama-shi, Kanagawa 221-0825, Japan
  • Osaka Habikino Medical Center
    Habikino-shi, Osaka 583-8588, Japan
  • Dermatology and Ophthalmology Kume Clinic
    Sakai-shi, Osaka 593-8324, Japan
  • Nihon University Itabashi Hospital
    Itabashi-ku, Tokyo 173-8610, Japan
  • NTT Medical Center Tokyo
    Shinagawa-ku, Tokyo 141-8625, Japan
  • Hallym University Dongtan Sacred Heart Hospital
    Hwaseong-si, Gyeonggi-do, 18450, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Hallym University Kangnam Sacred Heart Hospital
    Seoul, 07441, Korea, Republic of
  • Ajou University Hospital
    Suwon-si, Gyeonggi-do, 16499, Korea, Republic of
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-214, Poland
  • AMICARE z ograniczona odpowiedzialnoscia spolka komandytowa
    Lodz, 91-495, Poland
  • SPZOZ Centralny Szpital Kliniczny
    Lodz, 92-213, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie
    Lublin, 20-081, Poland
  • Clinical Research Center Spzoo Medic-R Spolka Komandytowa
    Poznan, 61-731, Poland
  • Kliniczny Szpital Wojewodzki nr 1 im Fryderyka Chopina
    Rzeszow, 35-055, Poland
  • Klinika Osipowicz and Turkowski Spzoo Opieka Wielospecjalistyczna Osipowicz and Turkowski
    Warszawa, 02-473, Poland
  • Wojskowy Instytut Medyczny
    Warszawa, 04-141, Poland
  • Hospital del Mar
    Barcelona, Cataluña 08003, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Cataluña 08041, Spain
  • Hospital Universitari de Bellvitge
    Hospitalet de LLobregat, Cataluña 08907, Spain
  • Hospital General Universitario de Valencia
    Valencia, Comunidad Valenciana 46014, Spain
  • Hospital Arnau de Vilanova de Valencia
    Valencia, Comunidad Valenciana 46015, Spain
09

References and documents

Publications

  • McLaren J, Chon Y, Gorski KS, Bernstein JA, Corren J, Hayama K, Jain V, Lima H, Sofen H, Ponnarambil S, Molfino NA, Maurer M. Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study. J Allergy Clin Immunol. 2025 Feb 14:S0091-6749(25)00172-1. doi: 10.1016/j.jaci.2025.01.045. Online ahead of print. PubMed 39956278 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Dec 2022, 20 months.

Results were first posted in May 2024, 1 year 4 months after primary completion. A results delay was requested in Aug 2023.

Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2021
First posted
Apr 6, 2021
StartActual
Apr 15, 2021
Primary completionActual
Dec 20, 2022
CompletionActual
Apr 13, 2023
Results delay requested
Aug 25, 2023
Results first posted
May 1, 2024
Last update
Apr 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04833855
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 6, 2021
Start date
Apr 15, 2021
Primary completion
Dec 20, 2022
Completion
Apr 13, 2023
Results posted
May 1, 2024
Last update
Apr 9, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion